Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

A hand in a medical or laboratory glove holds a laboratory flask with coins with dollar sign. Investments in laboratory research and science. Concept of profit, making money, business. Modern design. Copy space.

VC Financings Drop 20% in Q1 but Megarounds Keep Median Deal Size High

Biopharma venture capital fundraising declined from $8.1 billion in the first quarter of 2024 to $6.5 billion in the first three months of this year, headlined by a clutch of massive funding rounds.

May 6, 2025

2 min read

Annalee Armstrong

Brain shaped maze. Conceptual image of science and medicine. 3D illustration.

ALS

Lilly Deepens ALS Pipeline With $415M Alchemab Licensing Deal

The Alchemab deal will further strengthen Lilly’s early-stage pipeline for amyotrophic lateral sclerosis, coming less than a year after the pharma licensed QurAlis’ antisense oligonucleotide to correct a specific protein alteration in ALS.

May 6, 2025

2 min read

Tristan Manalac

Pictured: Bristol Myers Squibb office in California

Manufacturing

BMS Pledges $40B Investment in US Despite Cost-Cutting Plans

In light of President Donald Trump’s impending pharma tariffs, several big companies have made massive manufacturing investments in the U.S., including Eli Lilly, Johnson & Johnson and Novartis. BMS is the latest to make a multibillion-dollar push.

May 6, 2025

2 min read

Tristan Manalac

Robert F Kennedy Jr speaking at the White House

Legal

States Sue RFK Jr., Makary, Seeking To Block HHS Cuts

Twenty attorneys general allege that the recent workforce reduction at the Department of Health and Human Services is unlawful and could have potentially irreversible consequences.

May 6, 2025

2 min read

Tristan Manalac

Fashionable halftone collage. Concept of analytics, business data, financial planning, investment,report. Trendy modern retro illustration. Vector illustration

Earnings

Vertex Shrugs Off Q1 Miss With ‘Strong’ Journavx Launch, Encouraging Pipeline Position

Vertex has recorded some 25,000 prescriptions for Journavx since its January approval and is in the process of getting big PBMs to cover the non-opioid pain drug.

May 6, 2025

2 min read

Tristan Manalac

Brain with pills, Alzheimer awareness day, dementia diagnosis, Parkinson disease, memory loss disorder, damaged mind

Huntington’s disease

PTC Nosedives Despite Claiming Phase II Win for Huntington’s Hopeful

The biotech’s Huntingtin-targeting molecule lowered blood levels of the protein and elicited functional improvements in earlier-stage patients, but results were not as robust in other biomarkers or with patients at later stages of the disease.

May 5, 2025

2 min read

Dan Samorodnitsky

Pictured: BMS sign on a building in San Diego, California/iStock, JHVEPhoto

Layoffs

BMS Axes 516 More Employees in New Jersey

Bristol Myers Squibb has made significant cuts to its workforce since last year as part of a strategic reorganization aimed at saving $3.5 billion through 2027. The latest cuts in Lawrenceville, New Jersey, bring that area’s total number of disclosed cuts this year to 806.

May 5, 2025

2 min read

Angela Gabriel

Sign outside BioNTech's building in Germany

Earnings

BioNTech’s Ambitious PD-L1/VEGF Plans Currently Rely on Chinese Manufacturing

BNT327, a PD-L1/VEGF therapy, is still currently being manufactured in China, but BioNTech is working to establish a diversified supply chain, executives said during the company’s Q1 investor call.

May 5, 2025

3 min read

Tristan Manalac